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Purpose: To determine whether patients with sporadic, non-familial keratoconus and no pathogenic mutations in the
visual system homeobox 1 (VSX1) gene have evidence of chromosomal copy number alterations.
Methods: Twenty Saudi Arabian patients with isolated keratoconus, no family history of the disease and no mutations in
VSX1 were recruited. Additionally, 10 ethnically-matched healthy controls were also recruited for this study. We screened
patients for chromosomal copy number aberrations using the Agilent Human Genome CGH 244A Oligo Microarray Chip.
Results: None of the keratoconus patients screened had evidence of chromosomal copy number alterations when compared
to normal ethnically matched controls.
Conclusions: Chromosomal deletions and/or duplications were not detected in any of the patients tested here. Other
chromosomal imbalances such as translocations, inversions, and some ploidies cannot be detected by current array CGH
technology and other nuclear genetic or epigenetic factors cannot be excluded as a possible contributing factor to
keratoconus pathogenesis.
Keratoconus  (KTCN;  OMIM  148300)  is  a  non-
inflammatory thinning and anterior protrusion of the cornea
that results in steepening and distortion of the cornea, altered
refractive powers, and altered visual acuity. In more advanced
cases,  corneal  scarring  from  corneal  edema,  and
decompensation further reduces visual acuity. Symptoms are
highly variable and depend on the stage of progression of the
disorder [1]. The incidence of Keratoconus ranges between
1/500 to 1/2000 individuals throughout the world [2]. The
disease occurs with no ethnic or gender preponderance and
causes  significant  visual  impairment  [2-4].  Most  cases  of
keratoconus  are  sporadic  but  a  minority  (5%–10%)  has
positive family history [3,5]. In such cases both autosomal
recessive  and  dominant  patterns  of  inheritance  have  been
reported [6-9]. There are several chromosomal loci and genes
reported to be associated with keratoconus [3,9]. However,
some  were  eventually  excluded  [3,10],  while  others  no
confirmed association with the disease have been established
[11,12]. This is not the case for the visual system homeobox
1 (VSX1) gene where mutations associated with keratoconus
cases have been found in different studies [13-16]. Other
studies did not report VSX1 mutations in diverse population
cohorts  of  keratoconus  patients  [17,18],  including  Saudi
keratoconus patients [19]. This indicates that keratoconus is a
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complex  condition  of  multi-factorial  etiology  and  that
mutations  in  VSX1  are  not  responsible  for  all  cases  of
keratoconus.
Keratoconus can be divided into three broad categories:
i) keratoconus associated with rare genetic disorders (such as
Down syndrome, nail-patella syndrome, neurofibromatosis,
etc);  ii)  keratoconus  in  the  setting  of  commonly  reported
associations (contact lens wear, eye rubbing, atopy, Leber
congenital  amaurosis,  mitral  valve  prolapsed  and  positive
family  history)  and  iii)  isolated  keratoconus  with  no
associations. To our knowledge, no study has investigated
chromosomal copy number variations in patients with any of
the three types of keratoconus mentioned above.
Here  we  investigate  the  possible  presence  of
chromosomal copy number changes in patients with isolated
non-familial  keratoconus  using  high  resolution  array
comparative genomic hybridization (array CGH) technology.
To  our  knowledge,  this  investigation  was  not  performed
anywhere else previously.
METHODS
Patients and controls: Patients were selected from the anterior
segment clinic at King Abdulaziz University Hospital, King
Saud  University  in  Riyadh,  Saudi  Arabia  after  full
ophthalmological examination by anterior segment specialists
(A.A. and H.K.). Patients were diagnosed with keratoconus if
the  Schimpff-flow  based  elevation  map  showed  posterior
corneal elevation within the central 5 mm ≥+20 µm, inferior-
superior dioptric asymmetry (I-S value) >1.2 Diopter (D) and
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822the steepest keratometrey >47 D [20-22]. We have chosen
these  parameters  to  exclude  cases  that  are  keratoconus
suspects and to confine our study group to only cases with
definite keratoconus. All our patients were examined by a
specialist and established to be free of any genetic disorder
commonly associated with keratoconus [3,21]. Patients were
labeled as sporadic after examining the immediate family
members  and  identifying  the  patient  as  isolated  case  of
keratoconus.  Exclusion  criteria  was  post-LASIK  (laser-
assisted in situ keratomileusis), ectasia, or has a family history
of keratoconus or more than one individual from the same
immediate family were affected. All study subjects were self
identified of Saudi Arabian ethnicity. Family names were all
present in the database of Arab families of Saudi Arabian
origin. All keratoconus cases secondary to causes like trauma,
surgery, Ehlers Danlos syndrome, osteogenesis imperfecta
and pellucid marginal degeneration were excluded from the
study.
The  controls  were  recruited  from  the  general
ophthalmology clinic that had no ocular disease(s) or previous
ophthalmic  surgeries.  Their  slit  lamp  exam  showed  clear
cornea  and  their  Schimpff-flow  based  elevation  map  was
within normal limit. This research adhered to the tenets of the
Declaration of Helsinki, and all patients and controls signed
an  informed  consent  approved  by  the  institutional  review
board.
Array CGH technique: Blood was collected in ACD tubes and
DNA extracted using the Qiagen Autopure LS instrument
(Qiagen,  Valencia,  CA)  following  the  manufacturer
recommended  procedure.  To  detect  chromosomal
rearrangements, 2 μg of keratoconus patient genomic DNA
was competitively hybridized with 2 μg of ethnicity matched
control DNA (as a reference sample) on an Agilent Human
Genome  CGH  244A  Oligo  Microarray  Kit  (Agilent
Technologies, Inc., Santa Clara, CA), which has an average
probe spacing across the human genome of 6.4 Kb. Briefly,
3 μg of DNA from keratoconus patients and controls was
digested using 50 units of Alu1 (Roche, Mannheim, Germany)
and 50 units of Rsa1 (Roche) restriction enzymes in a 100 μl
volume with 10 μl 10× Promega Buffer C. Digestions were
performed for 2 h at 37 °C. Digested samples were purified
using QIAprep Spin Miniprep columns (Qiagen) and eluted
according to the manufacturer's instructions. Samples were
then analyzed using the Agilent 2100 Bioanalyzer with the
DNA  7500  LabChip  Kit  and  DNA  7500  Software  Script
(Agilent) as per the manufacturer’s instructions. Alu1/Rsa1
digested  DNA  samples  were  labeled  using  the  BioPrime
Array  CGH  Labeling  Kit  (Invitrogen,  Carlsbad,  CA)
according to the manufacturer's protocol. Keratoconus patient
and control DNA samples were systematically labeled with
Alexa Fluors 555 and 647, respectively.
Labeled products of each sample and control DNA were
purified using QIAprep Spin Miniprep columns (Qiagen),
mixed together, and checked on the Agilent 2100 Bioanalyzer
(Agilent) to evaluate the Alexa Fluors 555 integration into the
DNA samples. The following hybridization blocking reagents
were added to the purified Alexa Fluors 555 and 647 labeled
samples: 50 μg Cot-1 DNA (Invitrogen) and 50 μl 10× control
targets (Agilent). The volume was brought to 250 μl with
ddH2O, and 250 μl 2× hybridization buffer (Agilent) was
added.  The  hybridization  mixture  was  then  denatured  at
100 °C for 3 min in a water bath. Samples were immediately
transferred to a 37 °C water bath for 30 min to allow pre-
annealing  of  the  blocking  agents  to  the  labeled  sample.
Samples  were  centrifuged  for  5  min  at  16,000×  g  and
immediately applied to the Agilent Human Genome CGH
244A  Oligo  Microarray  Kit  (Agilent)  as  per  the
manufacturer's  recommendations.  Hybridizations  were
performed at 65 °C for 42 h.
Microarrays were disassembled in Agilent wash buffer-1
at room temperature (RT), transferred to a slide holder, and
incubated for 5 min with stirring in the Agilent wash buffer-1
at RT. The second washing step was performed for 1 min in
wash buffer-2 at 37 °C. The third and fourth washing steps
were done with acetonitrile (Fisher Scientific, Fair Lawn, NJ)
and  stabilization  solutions  (Agilent)  for  1.5  min  at  RT,
respectively. Microarray slides were immediately scanned in
the  Agilent  DNA  Microarray  Scanner  using  the  default
settings.
Data  analysis  was  performed  using  Agilent  Feature
Extraction  9.1  and  CGH  Analytics  3.4  (Agilent).  Log2
expression ratios were computed and normalized using CGH
Analytics 3.4 software. Putative chromosome copy number
changes  were  defined  by  intervals  of  3  or  more  adjacent
probes with log2 ratios suggestive of a deletion or duplication
when compared with the log2 ratios of adjacent probes. The
quality-weighted interval score algorithm (ADM2) was used
to compute and assist in the identification of aberrations for a
given sample. A more detailed protocol of the array CGH
protocol using the Agilent platform was previously reported
[23].
As an internal quality control measure, DNA from Saudi
keratoconus-patients were mixed with DNA from controls
(free of keratoconus) of the same and the opposite sex and co-
hybridized to the 244K Agilent-chip (Figure 1).
RESULTS
Clinical  characteristics  of  the  20  keratoconus  patients
included in this study are detailed in Table 1. None of our
patients had a family history of keratoconus and all were the
only affected members of their respective family. Patient sex
(9 males and 11 females) and mean age of 25.4 (SD 7.3) and
ethnicity matched controls (5 males and 5 females) with a
mean age of 58 (SD 15) were clinically evaluated as detailed
in the methods. Patient charts were reviewed carefully and all
patients were defined as isolated keratoconus cases with no
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823association  with  genetic  or  systemic  disorder.  The  entire
Figure 1. Array CGH result for internal control. As an internal quality
control for the array CGH procedure, opposite sex control DNA was
hybridized against keratoconus DNA (ratio of +1 with regard to
chromosome X for XX keratoconus and XY control).
coding  region  of  VSX1  was  screened  and  no  pathogenic
mutation(s), either novel or previously reported were found
[19].
We  proceeded  with  screening  the  patients  for  gross
chromosomal abnormalities. The signal ratio of each patient
compared  to  a  simultaneously  tested  control  (patient-cy3/
control-cy5) documented the absence of chromosomal copy
number variations in any patient. Representative images of
array CGH results are shown in Figure 2.
DISCUSSION
The 20 patients reported here met rigorous clinical criteria for
clinically defined keratoconus as detailed in methods. They
were all sporadic cases and were identified as Saudi Arabians.
We also recruited 10 healthy controls (free of keratoconus).
Mutations in VSXI have been identified in association with
keratoconus [13-15], but in our cohort, we did not detect any
Figure 2. Array CGH results for keratoconus patients versus controls.
Chromosomes shown were chosen randomly as representative of all
chromosomes  and  in  all  Keratoconus  patients  tested.  A:
Chromosome 16 and B: Chromosome 20. When control DNA was
hybridized against patient’s DNA, a signal ratio of zero (0) was
obtained,  indicating  the  absence  of  chromosomal  copy  number
alterations.
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824mutations in this gene [19]. This may not be surprising as the
role of VSXI in keratoconus is still ambiguous and many
studies in various populations found no mutations in this gene
in their respective populations [12,17,18,24]. Human VSXI is
a member of the CVC domain containing paired-like class of
homeo-proteins. VSXI expression in humans is detected in
embryonic  craniofacial,  adult  retinal,  and  adult  corneal
tissues. Previous studies have shown that the pathogenesis of
keratoconus is very complex and several gene- and gene-
environmental  interactions  play  a  critical  role  in  disease
prognosis.
Since its introduction as a technique to detect genomic
imbalances, array-based comparative genomic hybridization
(array  CGH)  has  revolutionized  our  understanding  of  the
structure of the human genome and greatly improved the study
of tumors and is rapidly becoming a new standard method for
clinical cytogenetics [25]. High resolution array CGH used
here  provides  quantitative  information  about  the  level  of
chromosome gain or loss, such as regions with high-level
amplification or high-magnitude deletion, and will recognize
a chromosomal duplication or deletion of a size of about ≥6
Kb. This technique did not detect any chromosomal copy
number  variations  of  this  size  in  keratoconus  patients  or
controls. These results indicate that it is very unlikely that
chromosomal  deletions  or  duplications  are  universally
responsible for isolated cases of keratoconus. Because of the
relatively  small  sample  size,  it  remains  possible  that
chromosomal aberrations might be present in a portion of
patients  with  isolated  keratoconus.  More  patients  from
multiple centers and various ethnicities would need to be
examined to make a general statement about the absolute
absence of chromosomal copy number variations in the setting
of isolated keratoconus. No comment can be made about other
chromosomal imbalances such as translocations, inversions,
and some ploidies because these cannot be detected by the
current array CGH technology.
In  summary,  we  used  high  resolution  array  CGH  to
evaluate a group of patients with isolated Keratoconus and
found no evidence of chromosomal copy number variations.
Therefore,  currently  neither  pathogenic  mutations  nor
chromosomal  deletions/duplications  provide  a  complete
explanation for isolated cases of Keratoconus in our patients.
TABLE 1. CLINICAL PHENOTYPES OF KERATOCONUS PATIENTS.
     Patient
demographics
  Uncorrected
   visual acuity
in Snellen’s chart Munsen sign Vogt's striae Hydrops Scarring
   Average
keratometry
    in VKG
 (in diopters)
   Optical
pachymetry
     (mm)
ID Age Sex OD OS OD OS OD OS OD OS OD OS OD OS OD OS
1 20 M 20/100 20/200 ++++++-+ 51.9 64.7 525 502
2 18 M CF 20/80 - - +++++ - 58 56 300 346
3 17 M CF 20/100 +-+ + ---- 60 56.6 455 509
4 35 F 20/20 20/60 ---+-+-+ 43.1 44.6 584 554
5 30 M 20/200 CF -------- 49.1 68.7 434 349
6 36 M 20/100 20/100 ---- + + - - 48.4 50.4 459 439
7 16 M CF CF ++++++-+ 54.4 55 241 268
8 24 M CF 20/80 ++++++++ 53 65.7 302 397
9 25 F CF CF ++++ - -+- 67.3 70.7 236 216
10 25 M 20/20 CF -+-+-+- - 43.1 50.9 419 407
11 32 F 20/40 20/40 ++++++ - - 43.5 51.7 442 398
12 20 F 20/25 20/100 ---+-+- - 42.7 56.2 509 456
13 32 F CF 20/200 ---- + + - - 56.3 52.6 429 471
14 17 F CF 20/25 +++-++++ 69.3 45.5 284 522
15 24 F 20/200 CF -+-+++-+ 49.8 62.2 492 218
16 39 F 20/200 20/200 ---- + + - - 49.2 53.1 458 419
17 25 M 20/40 CF ++++++-+ 42.8 43.7 482 511
18 17 F 20/60 20/100 + +-+++ - - 56.4 58.2 411 414
19 22 F 20/100 20/100 ---- + + - - 46.4 44.5 425 416
20 35 F CF CF -------- 43.6 63.1 482 371
       Key: M=Male; F=Female; OD=Right eye; OS=Left eye; +=Positive; -=Negative; VKG=Videokeratography; AD=Autosomal
       dominant; AR=Autosomal recessive; SP=Sporadic; ND=not determined due to difficulty in predicting the mode of inheritance
        from available family pedigree. All patients listed in this table were sporadic cases of keratoconus as determined by examining
        the family pedigree carefully and taking detailed family history up to 2–3 generations.
Molecular Vision 2011; 17:822-826 <http://www.molvis.org/molvis/v17/a93> © 2011 Molecular Vision
825Although unrecognized genetic or epigenetic factors may play
a role in keratoconus-pathogenesis.
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